Photodynamic therapy of cancer: An update

作者：Patrizia Agostinis, Kristian Berg, Keith A. Cengel, Thomas H. Foster, Albert W. Girotti, Sandra O. Gollnick, Stephen M. Hahn, Michael R. Hamblin, Asta Juzeniene, David Kessel, Mladen Korbelik, Johan Moan, Paweł Mróz, Dominika Nowis, Jacques Piette, Brian C. Wilson, Jakub Gołąb · 发表于：CA A Cancer Journal for Clinicians · 年份：2011 · DOI：10.3322/caac.20114 · 被引用次数：5162 · 研究领域：Photodynamic Therapy Research Studies、Nanoplatforms for cancer theranostics、Cancer, Hypoxia, and Metabolism

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.